Century Therapeutics IPO climbs to more than $242M; stock rises over 30%
Philadelphia-based cell therapy company has closed its $242.65 million initial public stock offering.
Article from Philadelphia Business Journal
Philadelphia-based cell therapy company has closed its $242.65 million initial public stock offering.
Article from Philadelphia Business Journal
Three life sciences companies have leased space for their headquarters, making long-term commitments to the Philadelphia region.
Article from Philadelphia Business Journal
Movement among company executives to rival firms is on the rise as the Philadelphia region’s cell and gene therapy industry advances.
Article from Philadelphia Business Journal
Drexel President is looking to the West and the South in search of future students.
Article from Philadelphia Business Journal